Company Overview
Company Type: Private Company
Website: microbioncorp.com
Global Number of Employees (Latest): -
Year Founded: 2000
Total Amount Raised (CAD mm)†: 60.39
Total Rounds of Funding**:7
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Microbion Corporation develops microbial bioenergetic inhibitors for the treatment of resistant and difficult-to-treat infections. It offers Pravibismane, an anti-infective drug that halts microbial cellular metabolism. The company develops bismuth-thiols for the treatment of chronic and acute wound infections and post-surgical orthopedic infections. It also offers methicillin-resistant staphylococcus aureus and other antibiotic-resistant microbes; products to treat moderate and severe diabetic foot ulcers/infections, orthopedic implant-related infections, and other chronic wounds; and products to reduce military wound-associated infections. Microbion Corporation was incorporated in 2000 and is based in Bozeman, Montana with an additional office in Vancouver, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
-
Net Debt
-
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Lalji, Karim F.
CEO & Director
Baker, Brett 
Founder, President, Chief Innovation Officer & Director
Kerins, Frank 
Member of Business Advisory Board
Memon, Muhammad 
Director of Finance
Lee, Edmond 
Senior Director of New Product Planning & Business Operations
Millard, Jeff 
Chief Scientific Officer
Mischke-Baker, Georgia
Director of Marketing & Communications and Member of Business Advisory Board
Nagy, Jon 
Vice President of Medicinal Chemistry and Member of Scientific Advisory Board

Key Board Members
Name
Title
Gillam, Robert Arthur
Chairman of the Board
Lalji, Karim F.
CEO & Director
Baker, Brett 
Founder, President, Chief Innovation Officer & Director
Kerins, Frank 
Member of Business Advisory Board
Mischke-Baker, Georgia
Director of Marketing & Communications and Member of Business Advisory Board
Nagy, Jon 
Vice President of Medicinal Chemistry and Member of Scientific Advisory Board
Harmon, Jason J.
Lead Director
Avnur, Zafrira 
Director
Carney, Jared 
Member of Business Advisory Board
Dolphin, David
Member of Scientific Advisory Board
Domenico, Philip
Member of Scientific Advisory Board
French, Christine
Member of Business Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
5 West Mendenhall Street Suite 202 | Bozeman, MT | 59715 | United States
Phone: 406 233 6472   Fax: 877 805 8377

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
5N Plus Inc. (TSX:VNP)
Jan-08-2021
Minority
-
Growth
GF Securities Co., Ltd., Investment Arm
Dec-30-2016
Unknown
-
Series A
Quark Venture Inc.
Dec-30-2016
Unknown
-
Series A
Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)
Feb-24-2016
Minority
4.60 %
Venture


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-08-2021
Jul-27-2021
Private Placement
Target
Microbion Corporation
5N Plus Inc. (TSX:VNP)

11.89
Dec-30-2016
Jan-05-2017
Private Placement
Target
Microbion Corporation
Quark Venture Inc.,GF Securities Co., Ltd., Investment Arm Buyer Funds:Global Health Sciences Venture Fund

25.37
Feb-24-2016
Mar-02-2016
Private Placement
Target
Microbion Corporation
Xizang Haisco Pharmaceutical Group Co., Ltd. (nka:Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653))

2.35
Jan-08-2014
Jan-22-2016
Private Placement
Target
Microbion Corporation


5.86
Oct-15-2012
-
Private Placement
Target
Microbion Corporation


1.25
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-05-2023
Company Conference Presentations
Microbion Corporation Presents at BioFuture 2023, Oct-04-2023 through Oct-06-2023
Mar-09-2023
Product-Related Announcements
Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections
Feb-06-2023
Company Conference Presentations
Microbion Corporation Presents at BIO CEO & Investor Conference 2023, Feb-06-2023 03:45 PM
Jan-09-2023
Company Conference Presentations
Microbion Corporation Presents at BIO Partnering at JPM 2023, Jan-09-2023
Nov-03-2022
Company Conference Presentations
Microbion Corporation Presents at North American Cystic Fibrosis Conference 2022, Nov-03-2022 through Nov-05-2022


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 04:16 AM
Microbion Corporation
Microbion Corp
Reports
67
GlobalData

Jul 27, 2023 07:01 AM
Microbion Corporation
Microbion Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Jun 28, 2023 04:12 AM
Microbion Corporation
Microbion Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Jun 15, 2023 06:19 AM
Microbion Corporation
Microbion Corp
Reports
63
GlobalData

Mar 17, 2023 05:47 AM
Microbion Corporation
Microbion Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Mar 15, 2023 01:39 AM
Microbion Corporation
Microbion Corp
Reports
59
GlobalData

Dec 14, 2022 02:38 AM
Microbion Corporation
Microbion Corp
Reports
66
GlobalData

Nov 24, 2022 04:09 AM
Microbion Corporation
Microbion Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
24
GlobalData

Sep 23, 2022 06:18 AM
Microbion Corporation
Microbion Corp
Reports
63
GlobalData

Aug 12, 2022 06:59 AM
Microbion Corporation
Microbion Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
24


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
MBN-101 (Future)


Upcoming Events
Date/Time
Type
Oct-10-2023
Company Conference Presentations
Oct-10-2023
Conferences
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Gillam, Robert Arthur
Chairman of the Board
406 233 6472
877 805 8377

Lalji, Karim F.
CEO & Director
406 233 6472
877 805 8377

Baker, Brett 
Founder, President, Chief Innovation Officer & Director
406 233 6472
877 805 8377

Kerins, Frank 
Member of Business Advisory Board
406 233 6472
877 805 8377

Mischke-Baker, Georgia
Director of Marketing & Communications and Member of Business Advisory Board
406 233 6472
877 805 8377
-
Nagy, Jon 
Vice President of Medicinal Chemistry and Member of Scientific Advisory Board
406 233 6472
877 805 8377

Harmon, Jason J.
Lead Director
406 233 6472
877 805 8377

Avnur, Zafrira 
Director
406 233 6472
877 805 8377

Carney, Jared 
Member of Business Advisory Board
406 233 6472
877 805 8377
-
Dolphin, David
Member of Scientific Advisory Board
406 233 6472
877 805 8377
-
Domenico, Philip
Member of Scientific Advisory Board
406 233 6472
877 805 8377
-
French, Christine
Member of Business Advisory Board
406 233 6472
877 805 8377
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Lalji, Karim F.
CEO & Director
406 233 6472
877 805 8377

Baker, Brett 
Founder, President, Chief Innovation Officer & Director
406 233 6472
877 805 8377

Kerins, Frank 
Member of Business Advisory Board
406 233 6472
877 805 8377

Memon, Muhammad 
Director of Finance
406 233 6472
877 805 8377

Lee, Edmond 
Senior Director of New Product Planning & Business Operations
406 233 6472
877 805 8377

Millard, Jeff 
Chief Scientific Officer
406 233 6472
877 805 8377

Mischke-Baker, Georgia
Director of Marketing & Communications and Member of Business Advisory Board
406 233 6472
877 805 8377
-
Nagy, Jon 
Vice President of Medicinal Chemistry and Member of Scientific Advisory Board
406 233 6472
877 805 8377

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
